A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
- Conditions
- Eczema
- Interventions
- Drug: Mucopolysaccharide Polysulfate CreamDrug: Mucopolysaccharide Polysulfate Cream and glucocorticoids
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05439577
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Phase 1
- Conditions
- Ovarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05273944
- Locations
- 🇨🇳
Sun Yat-Sun Memorial Hospital, Sun Yat-Sun University, Guangzhou, Guangdong, China
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT05108766
- Locations
- 🇨🇳
The First Affiliated Hospital of Air Force Medical University of PLA, Xi'an, China
A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition
Not Applicable
- Conditions
- Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT04057326
Expanding Phase III Study of Tyroserleutide for Injection
Phase 3
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 352
- Registration Number
- NCT03516448
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
Phase 3
- Conditions
- Hepatocellular,Carcinoma
- Interventions
- Drug: the placebo ,chemotherapy(mitomycin, and Fluorouracil )
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT01489566
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: mitomycin, Fluorouracil
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT00644020
- Locations
- 🇨🇳
A Research Institute of Tumor, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath